u/slow_logbook_notes30

Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.

a mean is not a promise

glycaemic control and weight are two different endpoints

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

Cosigning that postprandial excursions improve first and the fasting number is the laggard.

Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.

A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.

SELECT was cardiovascular outcomes, not weight

nausea profile in the combination trials is the thing to read carefully

What was the comparator?

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.

This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.

Read the phase 2 hepatic paper properly and the endpoint definitions were more interesting than the headline response rate.

Same. Very thin independent data on this one, which should make everybody here more tentative than they are.

REDEFINE is the combination programme

Bought small on anything without a testing history here. That rule has never once cost me anything.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

Not convinced. A purity figure without a stated method is not comparable to one that has a method attached.

Purity methods differ by compound class. A gradient and wavelength developed for one peptide will not necessarily resolve the relevant impurities of another.

Cosigning on the thin independent data. Fewer members test this, so the bands are wider and should be treated that way.

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

The three questions to ask before ordering anything from the long tail of a catalogue.

What exactly is it — catalogue number or sequence, not a common name, because several common names map to more than one molecule. How was identity established — mass against theoretical, ideally, rather than a bare purity figure. What are the storage conditions, stated specifically, with a state and a duration attached.

Then two commercial questions that save time: is this a stocked line or made to order, and what is the lead time in writing. All five are one email, and the shape of the reply tells you a great deal before any material moves.

Yes. Naming conventions in this corner are loose enough that the same word covers several different molecules.

Identifying details redacted from the exported report above.

This is the distinction that resolves most of the confusion here — average versus shape.

Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

Stocked lines and made-to-order lines have different lead times and different storage histories. Both are ordinary; the difference is worth confirming before you commit.

purity methods differ between compound classes

lead times on unusual lines are the thing to confirm up front

this is a less-travelled board and the evidence base shows it

check the trial population before quoting a result at somebody

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

Net peptide content on the certificate was well below the purity figure and both were honest. Chemistry, not deception.

Same. Very thin independent data on this one, which should make everybody here more tentative than they are.

The honest evidence position, written out so this board does not drift.

Phase 2 data exists in a specific, biopsy-characterised population, with a slow protocol escalation and tolerability tables worth reading in full. Nothing containing this compound is approved by any regulator anywhere. Research-use-only material is not approved for human use.

Independent purity results across this entire site number in the low single figures. That means nobody here — including the people who post most confidently — has a basis for statements about batch-to-batch consistency. If you test something, post it; the log is the only thing that will change that position.

Disagree — that is an obesity trial endpoint and this thread is about glycaemic control.

Correction: that name covers two different molecules and the thread has been discussing both as one.

Kept fingersticks alongside the sensor for two weeks to sanity-check it. Worth doing once.